Generics - North America, Johnson & Johnson

Filter

Popular Filters

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

FDA approval of generic cancer drug Doxil is expected to help resolve shortage

06-02-2013

The US Food and Drug Administration has approved the first generic version of the cancer drug Doxil (doxorubicin…

DoxilGenericsJohnson & JohnsonLipodoxNorth AmericaOncologyRegulationSun Pharmaceutical Industries

Impax Labs and Teva settle Concerta litigation with J&J units

17-09-2012

USA-based Impax Laboratories (Nasdaq: IPXL) and the US unit of Israel generics giant Teva Pharmaceutical…

ALZA CorpConcertaGenericsImpax LaboratoriesJanssenJohnson & JohnsonNeurologicalNorth AmericaPatentsTeva Pharmaceutical Industries

Johnson & Johnson close to settling over Risperdal marketing; SEC probes Teva

06-08-2012

US health care giant Johnson & Johnson (NYSE: JNJ) has reached "an agreement in principle'' with the…

FinancialGenericsInvegaJanssenJohnson & JohnsonLegalMarkets & MarketingNatrecorNorth AmericaPharmaceuticalRisperdalTeva Pharmaceutical Industries

FDA delays once-a-day Prezista approval; finds counterfeit of Teva's Adderall

30-05-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Therapeutics division has received a complete…

AdderallAnti-viralsGenericsJanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPrezistaRegulationTeva Pharmaceutical Industries

Watson settles with Janssen over Ortho Tri-Cyclen LO

08-02-2012

US generic drugmaker Watson Pharmaceutical (NYSE: WPI) says that its subsidiary, Watson Laboratories,…

GenericsJanssenJohnson & JohnsonLegalNorth AmericaPatentsReproductiveWatson PharmaceuticalsWomen's Health

Back to top